Abstract
The ability to recognize diverse clinical forms of xanthomas, such as tuberous, planar, eruptive and tendinous, is important in the detection of underlying systemic disease. A variety of primary genetic disorders, as well as numerous secondary conditions such as diabetes, obstructive liver disease, thyroid disease, renal disease, and pancreatitis, can lead to hyperlipoproteinemia that results in the formation not only of xanthomas but also of life-threatening vascular atherosclerosis. An understanding of the pathogenesis of the underlying lipoprotein alterations provides a rational approach to therapy utilizing dietary manipulations and drugs. Such treatment is capable of correcting most disorders of lipid metabolism, and, if appropriate therapy is initiated at the first sign of xanthoma evolution, it may prevent progression of atherosclerosis, provide resolution of xanthomas, and in some instances prevent serious pancreatitis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoproteins / metabolism
-
Arteriosclerosis / etiology
-
Cholestasis / complications
-
Cholestyramine Resin / therapeutic use
-
Clofibrate / therapeutic use
-
Colestipol / therapeutic use
-
Dextrothyroxine / therapeutic use
-
Diabetes Complications
-
Female
-
Humans
-
Hyperlipidemias / diagnosis*
-
Hyperlipidemias / etiology
-
Hyperlipoproteinemia Type III / metabolism
-
Hyperlipoproteinemia Type IV / metabolism
-
Hyperlipoproteinemias / genetics
-
Hypolipidemic Agents / therapeutic use
-
Hypothyroidism / complications
-
Kidney Diseases / complications
-
Lipoproteins / metabolism
-
Male
-
Neomycin / therapeutic use
-
Niacin / therapeutic use
-
Obesity / complications
-
Pancreatitis / complications
-
Xanthomatosis / diagnosis*
-
Xanthomatosis / drug therapy
-
Xanthomatosis / etiology
Substances
-
Apoproteins
-
Hypolipidemic Agents
-
Lipoproteins
-
Cholestyramine Resin
-
Niacin
-
Dextrothyroxine
-
Clofibrate
-
Neomycin
-
Colestipol